Cognition Therapeutics (CGTX) Free Cash Flow (2020 - 2026)
Cognition Therapeutics (CGTX) reported Free Cash Flow of -$5.5 million for Q1 2026, up 43.89% year-over-year from -$3.9 million in Q1 2025, and down 61.25% on a QoQ basis from -$3.4 million in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Free Cash Flow data on file, last reported at -$5.5 million in Q1 2026.
- Quarterly Free Cash Flow rose 43.89% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.3 million (up 34.89% YoY) and the FY2025 annual result came in at -$24.6 million, up 13.66% from the prior year.
- Free Cash Flow slipped to -$5.5 million in Q1 2026 per CGTX's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$27000.0 in Q3 2022 and bottomed at -$10.2 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$5.5 million (2026), against an average of -$5.5 million.
- The widest annual swing landed in 2022, when Free Cash Flow jumped 98.68%; it then plunged 15525.93% in 2023.
- Tracing CGTX's Free Cash Flow over 5 years: stood at -$10.2 million in 2022, then surged by 46.18% to -$5.5 million in 2023, then tumbled by 52.81% to -$8.4 million in 2024, then surged by 59.0% to -$3.4 million in 2025, then plunged by 61.25% to -$5.5 million in 2026.
- Per Business Quant, the three latest CGTX Free Cash Flow figures stand at -$5.5 million (Q1 2026), -$3.4 million (Q4 2025), and -$5.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 848.30 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -5.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.54 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Dec 31, 2025 | -3.44 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -5.62 Mn |
| Jun 30, 2025 | -5.62 Mn |
| Mar 31, 2025 | -9.88 Mn |
| Mar 31, 2025 | -9.88 Mn |
| Dec 31, 2024 | -8.38 Mn |
| Dec 31, 2024 | -8.38 Mn |
| Sep 30, 2024 | -6.85 Mn |
| Sep 30, 2024 | -6.85 Mn |
| Jun 30, 2024 | -6.00 Mn |
| Jun 30, 2024 | -6.00 Mn |
| Mar 31, 2024 | -7.24 Mn |
| Mar 31, 2024 | -7.24 Mn |
| Dec 31, 2023 | -5.49 Mn |
| Dec 31, 2023 | -5.49 Mn |
| Sep 30, 2023 | -4.22 Mn |
| Sep 30, 2023 | -4.22 Mn |
| Jun 30, 2023 | -3.71 Mn |
| Jun 30, 2023 | -3.71 Mn |
| Mar 31, 2023 | -2.75 Mn |
| Mar 31, 2023 | -2.75 Mn |
| Dec 31, 2022 | -10.19 Mn |
| Dec 31, 2022 | -10.19 Mn |
| Sep 30, 2022 | -27,000.00 |
| Sep 30, 2022 | -27,000.00 |
| Jun 30, 2022 | -5.36 Mn |
| Jun 30, 2022 | -5.36 Mn |
| Mar 31, 2022 | -3.12 Mn |
| Mar 31, 2022 | -3.12 Mn |
| Dec 31, 2021 | 101,000.00 |
| Dec 31, 2021 | 101,000.00 |
| Sep 30, 2021 | -2.05 Mn |
| Sep 30, 2021 | -2.05 Mn |
| Jun 30, 2021 | -910,000.00 |
| Jun 30, 2021 | -910,000.00 |
| Mar 31, 2021 | -772,000.00 |
| Mar 31, 2021 | -772,000.00 |
| Dec 31, 2020 | -480,000.00 |
| Dec 31, 2020 | -480,000.00 |